Analyzing Peak Bio (NASDAQ:PKBO) and Curis (NASDAQ:CRIS)
Analyzing Peak Bio (NASDAQ:PKBO) and Curis (NASDAQ:CRIS)
Peak Bio (NASDAQ:PKBO – Get Rating) and Curis (NASDAQ:CRIS – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and valuation.
Peak Bio（纳斯达克股票代码：PKBO — 获取评级）和Curis（纳斯达克股票代码：CRIS — 获取评级）都是小型医疗公司，但哪个是更好的投资？我们将根据两家公司的股息、盈利能力、机构所有权、风险、分析师建议、收益和估值进行比较。
Institutional and Insider Ownership
机构所有权和内部所有权
64.4% of Peak Bio shares are held by institutional investors. Comparatively, 38.7% of Curis shares are held by institutional investors. 19.9% of Peak Bio shares are held by insiders. Comparatively, 6.2% of Curis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Peak Bio的64.4％股票由机构投资者持有。相比之下，38.7％的Curis股票由机构投资者持有。19.9％的Peak Bio股票由内部人士持有。相比之下，6.2％的Curis股份由内部人士持有。强大的机构所有权表明，对冲基金、大型基金经理和捐赠基金认为，从长远来看，公司的表现将超过市场。
Profitability
盈利能力
This table compares Peak Bio and Curis' net margins, return on equity and return on assets.
该表比较了Peak Bio和Curis的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Peak Bio | N/A | N/A | -1.34% |
| Curis | -566.41% | -82.91% | -42.52% |
| 净利润 | 股本回报率 | 资产回报率 | |
| 峰值生物 | 不适用 | 不适用 | -1.34% |
| 库里斯 | -566.41% | -82.91% | -42.52% |
Analyst Recommendations
分析师建议
This is a breakdown of current ratings for Peak Bio and Curis, as provided by MarketBeat.com.
这是Marketbeat.com提供的Peak Bio和Curis当前评级的明细。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Peak Bio | 0 | 0 | 1 | 0 | 3.00 |
| Curis | 0 | 1 | 3 | 0 | 2.75 |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| 峰值生物 | 0 | 0 | 1 | 0 | 3.00 |
| 库里斯 | 0 | 1 | 3 | 0 | 2.75 |
Peak Bio presently has a consensus target price of $15.00, indicating a potential upside of 1,899.73%. Curis has a consensus target price of $7.67, indicating a potential upside of 1,004.71%. Given Peak Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Peak Bio is more favorable than Curis.
Peak Bio目前的共识目标价为15.00美元，表明潜在的上涨空间为1,899.73％。Curis的共识目标价为7.67美元，表明潜在的上涨空间为1,004.71％。鉴于Peak Bio更高的共识评级和更高的上行空间，股票研究分析师显然认为Peak Bio比Curis更有利。
Volatility & Risk
波动性与风险
Peak Bio has a beta of -0.6, indicating that its stock price is 160% less volatile than the S&P 500. Comparatively, Curis has a beta of 2.88, indicating that its stock price is 188% more volatile than the S&P 500.
Peak Bio的beta值为-0.6，这表明其股价的波动性比标准普尔500指数低160％。相比之下，Curis的beta值为2.88，这表明其股价的波动性比标准普尔500指数高188％。
Earnings and Valuation
收益和估值
This table compares Peak Bio and Curis' revenue, earnings per share and valuation.
该表比较了Peak Bio和Curis的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Peak Bio | N/A | N/A | -$490,000.00 | N/A | N/A |
| Curis | $10.65 million | 6.28 | -$45.44 million | ($0.64) | -1.08 |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| 峰值生物 | 不适用 | 不适用 | -490,000.00 美元 | 不适用 | 不适用 |
| 库里斯 | 1,065 万美元 | 6.28 | -4544 万美元 | (0.64 美元) | -1.08 |
Peak Bio has higher earnings, but lower revenue than Curis.
与Curis相比，Peak Bio的收益更高，但收入更低。
Summary
摘要
Peak Bio beats Curis on 8 of the 11 factors compared between the two stocks.
与两只股票相比，Peak Bio在11个因素中的8个方面击败了Curis。
About Peak Bio
关于匹克生物
(Get Rating)
（获取评分）
Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. Its lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is headquartered in Palo Alto, California.
Peak Bio, Inc. 是一家临床阶段的生物制药公司，专注于开发治疗炎症、癌症以及罕见和特殊疾病患者的疗法。其主要候选产品是 PHP-303，它正处于治疗 α-1 抗胰蛋白酶缺乏症和急性呼吸窘迫综合征的 2 期临床研究。它还开发了 Trop2 PH1，一种治疗实体瘤的抗体药物偶联物。该公司成立于2020年，总部位于加利福尼亚州帕洛阿尔托。
About Curis
关于 Curis
(Get Rating)
（获取评分）
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Curis, Inc. 从事用于治疗人类癌症的候选药物的开发和商业化。其产品线包括 CUDC-907、CA-4948、CA-170 和 CA-327。CUDC-907 管道是一种口服的 HDAC 和 PI3K 酶小分子抑制剂。CA-170 管道也是 PD-L1 和 VISTA 免疫检查点的口服小分子拮抗剂。该公司成立于 2000 年 2 月 14 日，总部位于马萨诸塞州列克星敦。
Receive News & Ratings for Peak Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peak Bio and related companies with MarketBeat.com's FREE daily email newsletter.
接收Peak Bio Daily的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Peak Bio及相关公司的最新新闻和分析师评级的简明每日摘要。